https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-12-24 / Cancers (Basel) 2020 Dec;13(1)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-12-24 / Cancers (Basel) 2020 Dec;13(1)2020-12-24 00:00:002021-11-15 13:17:14Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-12-08 / PeerJ 2020;8:e9761
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-12-08 / PeerJ 2020;8:e97612020-12-08 00:00:002020-12-08 00:00:00Oncolytic effects of the recombinant Newcastle disease virus, rAF-IL12, against colon cancer cells in vitro and in tumor-challenged NCr-Foxn1nu nude mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-11-28 / Cancers (Basel) 2020 Nov;12(12)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-11-28 / Cancers (Basel) 2020 Nov;12(12)2020-11-28 00:00:002022-10-30 16:29:37Newcastle Disease Virus at the Forefront of Cancer Immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-11-16 / Int J Mol Sci 2020 Nov;21(22)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-11-16 / Int J Mol Sci 2020 Nov;21(22)2020-11-16 00:00:002020-12-07 09:22:05Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-10-26 / Oncologist 2020 Oct;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-10-26 / Oncologist 2020 Oct;2020-10-26 00:00:002020-10-26 00:00:00Emerging Immunotherapies in the Treatment of Brain Metastases
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-10-01 / Arch Razi Inst 2020 10;75(3):367-376
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-10-01 / Arch Razi Inst 2020 10;75(3):367-3762020-10-01 00:00:002021-05-12 07:45:41Evaluation of Apoptosis Induction by Newcastle Disease Virus LaSota Strain in Human Breast Carcinoma Cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-09-28 / J Med Virol 2021 06;93(6):3890-3898
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-09-28 / J Med Virol 2021 06;93(6):3890-38982020-09-28 00:00:002020-09-28 00:00:00The recombinant Newcastle disease virus Anhinga strain expressing human TRAIL exhibit antitumor effects on a glioma nude mice model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-09-28 / J Cell Biochem 2021 Jan;122(1):3-15
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-09-28 / J Cell Biochem 2021 Jan;122(1):3-152020-09-28 00:00:002021-05-12 07:46:58NDV-D90 inhibits 17β-estradiol-mediated resistance to apoptosis by differentially modulating classic and nonclassic estrogen receptors in breast cancer cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-08-28 / Cancer Cell Int 2020;20:420
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-08-28 / Cancer Cell Int 2020;20:4202020-08-28 00:00:002020-08-28 00:00:00Hexokinase inhibition using D-Mannoheptulose enhances oncolytic newcastle disease virus-mediated killing of breast cancer cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-08-07 / Cancer Cell Int. 2020;20:380
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-08-07 / Cancer Cell Int. 2020;20:3802020-08-07 00:00:002020-08-07 00:00:00Synergy between hemagglutinin 2 (HA2) subunit of influenza fusogenic membrane glycoprotein and oncolytic Newcastle disease virus suppressed tumor growth and further enhanced by Immune checkpoint PD-1 blockade
